14

25 – 28 March 20
g
The Westin Beijin
Chaoyang, China

East Asia
provals in China &
ug & Clinical Trial Ap
Accelerating...
Upcoming SlideShare
Loading in...5
×

2nd Pharma Regulatory Asia in Beijing

75

Published on

With the growth and development of the biopharma industry and increasing changing legislations on areas like biosimilars, pediatric drug development and generic drugs in China and East Asia, now is the time for you to bring along your regulatory affairs teams to keep abreast of evolving regulatory environments and requirements at IBC’s 2nd Pharmaceutical Regulatory Summit in China.

http://www.pharmaregulatoryasia.com/

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
75
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "2nd Pharma Regulatory Asia in Beijing "

  1. 1. 14 25 – 28 March 20 g The Westin Beijin Chaoyang, China East Asia provals in China & ug & Clinical Trial Ap Accelerating Dr What’s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control, China Pediatric Investigational Plans (PIPs) MORE Drug Regulations & Case Studies Interactive & Open Discussion Session on Quality by Design (QbD) Electronic Regulatory Affairs Learn from China Industry Best Practices Discover Bridging Studies and Waiver Opportunities Pharmaceutical Marketing Regulations Drug-Device Combination Products 2014 Regulatory Experts Include: Prof. Ning Bao Ming Annette Chiu Stewart Geary Deputy Director, Division of Chemical Drugs/GMP Inspector, National Institute for Food and Drug Control, Agency of the CFDA, China Regulatory & Medical Affairs Director, GlaxoSmithKline, Chairperson of the Regulatory Affairs Committee, Hong Kong Association of the Pharmaceutical Industry, Hong Kong Vice President/Deputy Director, President, Corporate Regulatory BravoBio, China Compliance & QA, Eisai Japan, Director, The Japanese Association of Pharmaceutical Medication (JAPhMed), Japan Dr Wu Ke May Wei Global Regulatory Strategist, Bayer Healthcare, China PLUS! Informative Workshops on: PRE-CONFERENCE WORKSHOPS • 25 MARCH 2014 POST-CONFERENCE WORKSHOPS • 28 MARCH 2014 A Preparing and Submitting Dossiers for Generic Drug Approval B Gaining Global Approvals of Biosimilars C Regulatory Strategies for Emerging Market Access D Pediatric Drug Development www.pharmaregulatoryasia.com Produced by: Supporting Organisation: Media Partners: Life Sciences International Marketing Partner: REGISTER NOW! Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680

×